A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates [PDF]
An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Fernando Pasteran +13 more
doaj +2 more sources
Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates [PDF]
Carbapenems are commonly used to treat infections caused by multidrug-resistant (MDR) bacteria. Unfortunately, carbapenem resistance is increasingly reported in many gram-negative bacteria, especially Acinetobacter baumannii.
Jose Cedano +11 more
doaj +2 more sources
The addition of sulbactam restores the complete range of cefoperazone activity against bacteria and extends its spectrum of action to include the Acinetobacter species.
Chienhsiu Huang, Lichen Lin, Sufang Kuo
doaj +2 more sources
When the Antibiogram Offers Nothing Else: Ceftriaxone-Sulbactam-Disodium EDTA With Intravenous Colistin in Two Neonates With Metallo-β-Lactamase-Producing <i>Acinetobacter baumannii</i> Meningitis. [PDF]
ABSTRACT Two neonates with metallo‐β‐lactamase‐producing Acinetobacter baumannii meningitis, resistant to every tested alternative, received ceftriaxone–sulbactam–disodium EDTA plus intravenous colistin, which, to our knowledge, represents the first reported neonatal use of this combinations. Cultures were sterilized by day 7; both survived with normal
Puri N +5 more
europepmc +2 more sources
Clinical Outcomes of Pandrug-Resistant Versus Carbapenem-Resistant, Colistin-Susceptible <i>Acinetobacter baumannii</i> Infections: A Retrospective Analysis of a Prospective Multicentre Cohort. [PDF]
Background: Pandrug-resistant (PDR) Acinetobacter baumannii represents a major therapeutic challenge in regions where carbapenem-resistant A. baumannii (CRAB) is endemic.
Karaiskos I +20 more
europepmc +2 more sources
The objective of this study was to evaluate whether combinations of sulbactam, meropenem, and polymyxin-B could reduce or close the gap of mutant selection window (MSW) of individual antibiotics against Acinetobacter baumannii harboring OXA-23.
Jiayuan Zhang +15 more
doaj +1 more source
Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with broad spectrum activity against Ambler class A, C, and D serine β-lactamases.
Adam B. Shapiro +4 more
doaj +1 more source
This study aimed to assess the dosing regimens of ampicillin/sulbactam for pneumonia based on pulmonary pharmacokinetic (PK)/pharmacodynamic (PD) target attainment.
Tetsushu Onita +6 more
doaj +1 more source
High-dose Sulbactam Treatment for Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant [PDF]
Background Several antibiotics can be used to treat ventilator-associated pneumonia caused by carbapenem-resistant A. baumannii (CRAB-VAP) including high-dose sulbactam. However, the effectiveness of high-dose sulbactam therapy is not well known.
In Beom Jeong +4 more
doaj +1 more source
There has previously been a report of a patient developing haemolytic anaemia following exposure to cefoperazone. Another case has been reported involving the detection of cefoperazone-dependent antibodies in the absence of immune haemolytic anaemia.
Yuanjun Wu +7 more
doaj +1 more source

